W F Jungi
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Thürlimann B, Fey M, Senn H, Cavalli F, Jungi W, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9.
Jul 1, 1996First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Jul 1, 1996Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9
Thürlimann Beat, Fey M, Senn H J, Cavalli F, Jungi W F, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Borner M, Cavalli F, Thürlimann B, Jungi W, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071-7.
Oct 1, 1994First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Oct 1, 1994J Clin Oncol 1994; 12:2071-7
Borner M, Cavalli F, Thürlimann Beat, Jungi W F, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J P
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Thürlimann B, Morant R, Jungi W, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2:61-5.
Jan 1, 1994Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Jan 1, 1994Support Care Cancer 1994; 2:61-5
Thürlimann Beat, Morant R, Jungi W F, Radziwill A
[The malignant degeneration of Gorham-Stout disease?]
Fretz C, Jungi W, Neuweiler J, Haertel M. [The malignant degeneration of Gorham-Stout disease?]. RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1991; 155:579-81.
Dec 1, 1991[The malignant degeneration of Gorham-Stout disease?]
Dec 1, 1991RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1991; 155:579-81
Fretz C J, Jungi W F, Neuweiler Jörg, Haertel M
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
Morant R, Thürlimann B, Jungi W, Schmid L, Holdener E, Schmid U, Senn H. [Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]. Schweiz Med Wochenschr 1991; 121:344-6.
Mar 9, 1991[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
Mar 9, 1991Schweiz Med Wochenschr 1991; 121:344-6
Morant R, Thürlimann Beat, Jungi W F, Schmid L, Holdener E, Schmid U, Senn H J
Anthracycline-carboplatin combination in metastatic breast cancer
Thürlimann B, Senn H, Jungi W. Anthracycline-carboplatin combination in metastatic breast cancer. J Cancer Res Clin Oncol 1990; 116:13-4.
Jan 1, 1990Anthracycline-carboplatin combination in metastatic breast cancer
Jan 1, 1990J Cancer Res Clin Oncol 1990; 116:13-4
Thürlimann Beat, Senn H J, Jungi W F